The focus on four psychiatric disorders has made Lundbeck sell off two preclinical research projects to a US-based company founded by the former Vice President of the company's US research department. Lundbeck may still profit from the drugs, as there is an option for milestones and royalties.
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.